Monopar Therapeutics MNPR Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's net unrealized gains (losses) on securities still held?
- Monopar Therapeutics (MNPR) reported net unrealized gains (losses) on securities still held of -$32.68K in Q1 2026.
- How has Monopar Therapeutics's net unrealized gains (losses) on securities still held changed year-over-year?
- Monopar Therapeutics's net unrealized gains (losses) on securities still held decreased by 9544.5% year-over-year, from $346 to -$32.68K.
- What is the long-term trend for Monopar Therapeutics's net unrealized gains (losses) on securities still held?
- Over 3 years (2022 to 2025), Monopar Therapeutics's net unrealized gains (losses) on securities still held has grown at a 118.7% compound annual growth rate (CAGR), from $15.04K to $157.32K.
- What does net unrealized gains (losses) on securities still held mean?
- This metric represents the change in the fair value of investment securities held by the company that have not yet been sold. It reflects unrealized gains or losses that are recognized in equity rather than the income statement, providing a view of the market performance of the company's treasury or investment portfolio. This is a key indicator of the volatility associated with the company's idle capital assets.